EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Management of Advanced Renal Cell Carcinoma

Xin-Wen Zhang, Dirk Jäger, Stefanie Zschäbitz

Oncology Research and Treatment · 2025

DOI: 10.1159/000546879 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Oncology Research and Treatment, 2025. Verfasst von Xin-Wen Zhang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Heidelberg University Hospital, National Center for Tumor Diseases Heidelberg, Heidelberg, Germany. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background: Management of advanced renal cell carcinoma (RCC) has evolved significantly in the last years. Systemic treatment of clear cell RCC, the predominant subtype, is performed with immune checkpoint inhibitors (ICIs), anti-VEGF tyrosine kinase inhibitor (TKI), HIF2α inhibitors and mTOR inhibitors. Summary: The application of ICI in early disease has raised new challenges regarding subsequent therapy strategies and management of new toxicities of immunotherapy-based combination therapies. Systemic treatment for non-clear cell RCC is challenging due to the lack of robust clinical evidence for effective treatment regimens. Recent phase-2 data also indicate a benefit of ICI-combination therapies for non-clear cell RCC. For oligometastatic or oligoprogressive diseases, local therapy with cytoreductive nephrectomy, metastasectomy or stereotactic radiation can be considered. This review provides a comprehensive overview of current treatment strategies for advanced RCC, including systemic therapies for both clear cell and non-clear cell subtypes, management of treatment-associated toxicities, and the role of local therapies. Key Messages: Combination therapy for clear cell RCC is standard in first-line therapy and published data also support its use in non-clear cell carcinoma. Local therapies can be considered in selected patients. In subsequent treatment lines TKIs, mTOR inhibitors and the HIF2α inhibitor belzutifan are used.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsHumansCombined Modality TherapyImmune Checkpoint InhibitorsNephrectomyProtein Kinase InhibitorsMolecular Targeted TherapyAntineoplastic Combined Chemotherapy ProtocolsNeoplasm Staging

Stichwörter der Autor:innen

Checkpoint inhibitorHIF2α inhibitorMetastasectomyRenal cell carcinomaTyrosine kinase inhibitor

Substanzen

Immune Checkpoint InhibitorsProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Heidelberg University Hospital, National Center for Tumor Diseases Heidelberg, Heidelberg, Germany.
  • Heidelberg University Hospital, National Center for Tumor Diseases Heidelberg, Heidelberg, Germany, stefanie.zschaebitz@med.uni-heidelberg.de.

Zitieren

APA

Zhang, X. W., Jäger, D., & Zschäbitz, S. (2025). Management of Advanced Renal Cell Carcinoma. Oncology Research and Treatment. https://doi.org/10.1159/000546879

Vancouver

Zhang XW, Jäger D, Zschäbitz S. Management of Advanced Renal Cell Carcinoma. Oncology Research and Treatment. 2025. doi:10.1159/000546879

BibTeX
@article{Zhang2025,
  author = {Zhang, Xin-Wen and Jäger, Dirk and Zschäbitz, Stefanie},
  title = {Management of Advanced Renal Cell Carcinoma},
  journal = {Oncology Research and Treatment},
  year = {2025},
  doi = {10.1159/000546879}
}
Kostenlos starten →